Dashboard
High Debt Company with a Debt to Equity ratio (avg) at 1.99 times
- High Debt Company with a Debt to Equity ratio (avg) at 1.99 times
Positive results in Sep 26
Stock is technically in a Mildly Bullish range
With ROCE of 9.9, it has a Very Attractive valuation with a 2.1 Enterprise value to Capital Employed
Majority shareholders : Promoters
Market Beating performance in long term as well as near term
Total Returns (Price + Dividend) 
Raaj Medisafe for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Raaj Medisafe India Ltd Downgraded to Hold Amid Mixed Financial and Valuation Signals
Raaj Medisafe India Ltd, a micro-cap player in the packaging sector, has seen its investment rating downgraded from Buy to Hold as of 16 Nov 2026. This adjustment reflects a nuanced assessment across four key parameters: quality, valuation, financial trend, and technicals. Despite positive quarterly results and attractive valuation metrics, concerns over profitability erosion and debt servicing have tempered enthusiasm among analysts.
Read More
Raaj Medisafe India Ltd is Rated Buy by MarketsMOJO
Raaj Medisafe India Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 17 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 November 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read More
Raaj Medisafe India Ltd is Rated Buy by MarketsMOJO
Raaj Medisafe India Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 17 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 October 2026, providing investors with the latest insights into its performance and outlook.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
16-Nov-2026 | Source : BSEWe submit herewith News Paper cuttings containing Publication of Unaudited Financial Results for the quarter/Half year ended September 30 2026 published in Free Press and Chautha Sansar Indore edition dated November 15 2026.
Statement Of Deviation And/Or Variation Of Utilization Of Fuds For The Period From 01.07.2026 To 30.09.2026
13-Nov-2026 | Source : BSEWe submit herewith the Statement of deviation and/or variation of utilization of Funds for the quarter ended September 30 2026
Unaudited Financial Results-Sept 30 2026
13-Nov-2026 | Source : BSEWe submit herewith Unaudited Financial Results Segment Reporting Cash Flow Statement Statement of Assets and Liabilities for the quarter/Half year ended September 30 2026 which have been reviewed by the Audit Committee and taken on record by the Board of Directors in its meeting held on 13-11-2026. Limited Review Report dated 13-11-2026 issued by the Statutory Auditors of the Company is also attached.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 0 FIIs
Sushen Remedies Private Limited (15.4%)
Seema Patel (3.32%)
36.11%
Quarterly Results Snapshot (Standalone) - Sep'26 - YoY
YoY Growth in quarter ended Sep 2026 is 63.48% vs 68.65% in Sep 2025
YoY Growth in quarter ended Sep 2026 is -47.98% vs 78.35% in Sep 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 46.09% vs 7.87% in Sep 2024
Growth in half year ended Sep 2025 is 95.71% vs -3.55% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 44.50% vs 19.22% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 90.98% vs 1.14% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 28.18% vs 44.32% in Mar 2025
YoY Growth in year ended Mar 2026 is -70.47% vs 84.08% in Mar 2025